Clinical trial
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis…
NCT00052884 · Eastern Cooperative Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00052884 |
|---|---|
| Title | Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation |
| Official title | A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation |
| Enrollment | 8 |
| Start date | Jan 22, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 18, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: